Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance

Aspire Biopharma Holdings, Inc.

Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.
Notes proposal under Nasdaq Rule 5635(d) passed: 19,852,827 for, 3,747,867 against, 7,374,427 broker non-votes.
Reverse split ratio range 1:5 to 1:40; board has discretion to implement within one year.
Notes issued under Aug 19, 2025 purchase agreements; conversion floor price is 20% of 5-day avg closing prior to closing.
Ticker ASBP (common) and ASBPW (warrants) listed on Nasdaq.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.